CompletedPhase 1

The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause

Australia14 participantsStarted 2020-08-24

Plain-language summary

This is a pilot, multi-centre, open-label randomised controlled study to assess the early efficacy of intravenous (IV) administration of CYP-001 in adults admitted to an intensive care unit (ICU) with respiratory failure

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. P/F ratio \<300 mmHg
✓. Onset within one week of a known insult or new or worsening respiratory symptoms.
✓. Chest imaging shows bilateral opacities, which are not fully explained by effusions, lobar/lung collapse, or nodules.

What they're measuring

Trend in trajectory of PaO2/FiO2 ratio (P/F ratio) between groups

Timeframe: 7 days

Trial details

NCT IDNCT04537351

SponsorCynata Therapeutics Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-04-27

View on ClinicalTrials.gov More Covid19 trials